Anthracene nucleus antibiotic producing strain dnrX gene fragment, gene breaking engineering bacterium prepared from the same and application thereof

A gene fragment and antibiotic technology, applied in the field of genetic engineering, can solve the problems of low conversion rate, complex process, environmental pollution, etc., and achieve the effect of increasing yield

Inactive Publication Date: 2008-03-19
SHANGHAI INST OF PHARMA IND
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The process is complicated, the conversion rate is low, and it causes environmental pollution

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anthracene nucleus antibiotic producing strain dnrX gene fragment, gene breaking engineering bacterium prepared from the same and application thereof
  • Anthracene nucleus antibiotic producing strain dnrX gene fragment, gene breaking engineering bacterium prepared from the same and application thereof
  • Anthracene nucleus antibiotic producing strain dnrX gene fragment, gene breaking engineering bacterium prepared from the same and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1 PCR amplification dnrX' gene

[0033] Since only the dnrX gene sequence (accession number AF048833) derived from the daunorubicin-producing strain Streptomyces persei ATCC29050 has been published in GenBank, and there is no relevant report on the gene sequence outside the final codon. Given that the purpose of amplifying the gene is to block mutations, an incomplete gene can be amplified. Based on this, primers dnrX1 and dnrX2 were designed.

[0034] dnrX1 sequence: 5'-GGCCGCCAGCCGCTGTCCGA-3' (SEQ ID No.5)

[0035] dnrX2 sequence: 5'-GTGGTTCCAGGCGAAGAGCAGCGCATAGTC-3' (SEQ ID No.6)

[0036] PCR amplification was performed using the SIPI-1482 genome of S. coeruleorubidus as a template, and the reaction system was shown in Table 1:

[0037] Table 1 PCR reaction system composition

[0038] components

Final concentration

Dosage (μl)

10X reaction buffer MgCl 2 (15mmol / L)

5'-primer (10μmol / L)

3'-primer (10μmol / L)

Template...

Embodiment 2

[0042] Preparation and sequencing of the gene fragment dnrX" of embodiment 2dnrX'

[0043] The plasmid pYG957 was digested with Nco I, and the large fragment was recovered for self-ligation, transformed into DH5α competent cells, and the intermediate plasmid pYG962 was constructed (as shown in FIG. 4 ). The intermediate plasmid pYG962 was digested with KpnI and HindIII for verification, and pYG957 was digested with KpnI and HindIII for comparison. As shown in Figure 5, two bands of 1203bp and 2651bp were obtained by double enzyme digestion of pYG962, and two bands of 1080bp and 2651bp were obtained by double enzyme digestion of pYG957. , proving that the plasmid is correct.

[0044] Then, dnrX" was obtained by digestion with KpnI+HindIII from plasmid pYG962. The measured sequence is shown in SEQ ID No.3 in the sequence listing, and the encoded amino acid sequence is shown in SEQ ID No.4.

Embodiment 3

[0045] Example 3 Construction and Verification of Destroying dnrX Using Single Exchange to Block Mutation Plasmid pYG963

[0046] The dnrX" gene fragment obtained from plasmid pYG962 digested with KpnI+HindIII and the apramycin resistance gene apr (GenBank accession number: AJ566337, commercially synthesized by Yingjun Company) were connected to the vector pBluescript2KSM and constructed into recombinant plasmid pYG963 (As shown in Figure 6), transform DH5α competent cell, screen transformant with apramycin and ampicillin resistance.Extract plasmid and carry out PCR verification and enzyme digestion verification, as shown in Figure 7.With dnrX1 and dnrX2 as primer PCR, the partial gene dnrX' (1080bp) that can be amplified to dnrX gene with plasmid pYG957 as template, but can't with pYG963, as shown in Figure 7 (A), accords with expected result.With the total on the original vector and insert The pYG963 digestion site Sal I was verified by pYG963, and the bands of 4689bp and 61...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a nucleotide sequence which roots in an anthracycline and produces the partial gene dnrX1 and the gene fragment dnrX 2 of the dnrX 1 of streptomyces coeruleorubidus (Streptomyces coeruleorubidus), and an express vector containing the sequences. The present invention also discloses a gene disruption engineering strain which disrupts the treptomyces coeruleorubidus of the dnrX gene by adopting the express vectors with an exchange and homologous recombination method. When the gene disruption engineering strain is used to produce the anthracycline, the acidizing treatment is not required, adriacin which is not produced by a wild fungus can be produced, and the output of the adriacin and the daunorubicin can be greatly increased.

Description

technical field [0001] The invention relates to the field of genetic engineering, in particular to a dnrX gene segment of an anthracycline antibiotic-producing bacterium, a gene-blocking engineering bacterium prepared from the gene segment, and an application thereof. Background technique [0002] Anthracycline antibiotics, such as daunorubicin (DNR) and doxorubicin (DXR), are clinically used as first-line antineoplastic drugs, and doxorubicin is a derivative product of the C-14 hydroxylation of daunorubicin. Erythromycin has a wider anti-tumor spectrum and lower toxicity and side effects. At present, doxorubicin is produced industrially by chemical semi-synthesis, and doxorubicin is obtained from daunorubicin produced by microorganisms through a seven-step reaction. The process is complicated, the conversion rate is low, and it causes environmental pollution. [0003] Foreign studies on the biosynthetic pathway of daunorubicin-producing bacteria have shown that in the bio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/31C07K14/37C12N1/15C12P19/56
Inventor 朱春宝宫倩胡又佳朱宝泉
Owner SHANGHAI INST OF PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap